The MGFT department is also accredited with ISO 15189 for the genetic test of RET proto-oncogene and since 2002 has performed more than 500 tests in patients with clinical MEN2 manifestations i.e. medullary thyroid carcinoma (MTC), pheochromocytoma, hyperparathyroidism and cutaneous lichen amyloidosis (Fig. 4). Here, RET is linked to pheochromocytoma.